research Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
Search
for
Sort by
Research
390-420 / 1000+ results research INIBIDORES DA JANUS QUINASE PARA O TRATAMENTO DA ALOPECIA AREATA
JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
research Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure
Hepatitis B virus exposure may be linked to increased risk of alopecia areata.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Alopecia areata mit gutem Ansprechen auf Tofacitinib
Tofacitinib helped regrow hair in a woman with alopecia areata.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
research Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
M50054 may help treat hepatitis and hair loss from chemotherapy.
research In reply
Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
Baricitinib is effective and safe for treating severe alopecia areata.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Single-Administration Long-Acting Microarray Patch with Ultrahigh Loading Capacity and Multiple Releases of Thermally Stable Antibodies
A new patch can deliver stable antibodies over time for potential HIV treatment.
research New tool in our arsenal: efficacy of injectable platelet-rich fibrin (i-PRF) in androgenetic alopecia treatment
Injectable platelet-rich fibrin effectively improves hair density and scalp symptoms in androgenetic alopecia.
research Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment
Budesonide alone is less effective than standard treatment for autoimmune hepatitis.
research Leflunomide for the treatment of trichodysplasia spinulosa in a liver transplant recipient
Leflunomide successfully treated a rare skin condition in a liver transplant patient.
research Comparative Study Between BCG and Intralesional Steroid Injection in Treatment of Patchy Alopecia Areata
Intralesional triamcinolone acetonide is preferred for treating patchy alopecia areata due to fewer side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
research PD23-01 INHIBITOR OF 5A-REDUCTASE TYPES II PROMOTES THE INFILTRATION OF CD8+T CELLS IN BPH TISSUES.
Finasteride increases CD8+ T cells in BPH tissues.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Evaluation of Serum Toll-Like Receptor 4, Interferon Gamma, and Interleukin-17 Levels in Iraqi Patients with Alopecia Areata
Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Ritlecitinib is safe and may effectively treat alopecia areata.
research Psoriasis Course in Patients with Alopecia Areata Undergoing Baricitinib Therapy
Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.